Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Abstract Aims In symptomatic patients with heart failure and reduced ejection fraction (HFrEF), recent international guidelines recommend initiating four major therapeutic classes rather than sequential initiation.